Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Österborg

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Medical Oncology (Northwood, London, England)|March 2, 2011
RETRACTED ARTICLE: Survival of MM cells is dependent on Notch signalingPeter H Wiernik, Anders Österborg
Cancer Treatment Reviews|December 11, 2012
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignanciesMarcin Okroj, Anders Österborg, Anna M Blom
Frontiers in Immunology|July 19, 2021
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune EffectsMarzia Palma, Tom A Mulder, Anders Österborg
Medical Oncology (Northwood, London, England)|November 8, 2013
Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complementMarcin Okroj, Ingrid Eriksson, Anders Österborg, et al.
Cancer Treatment Reviews|March 20, 2016
New perspectives on complement mediated immunotherapyGrzegorz Stasiłojć, Anders Österborg, Anna M Blom, et al.
Cancers|July 3, 2019
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical ApplicationTom A Mulder, Björn E Wahlin, Anders Österborg, et al.
Molecular Immunology|March 22, 2015
Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activationAnna M Blom, Anders Österborg, Tom E Mollnes, et al.
British Journal of Haematology|July 6, 2017
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I studyMaria Winqvist, Marzia Palma, Kia Heimersson, et al.
Experimental Hematology|September 2, 2015
Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative studySandra Eketorp Sylvan, Henriette Skribek, Stefan Norin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 10, 2018
CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production ProfileIsabelle Magalhaes, Ingrid Kalland, James N Kochenderfer, et al.
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Medical Oncology (Northwood, London, England)|March 2, 2011
RETRACTED ARTICLE: Survival of MM cells is dependent on Notch signalingPeter H Wiernik, Anders Österborg
Cancer Treatment Reviews|December 11, 2012
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignanciesMarcin Okroj, Anders Österborg, Anna M Blom
Frontiers in Immunology|July 19, 2021
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune EffectsMarzia Palma, Tom A Mulder, Anders Österborg
Medical Oncology (Northwood, London, England)|November 8, 2013
Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complementMarcin Okroj, Ingrid Eriksson, Anders Österborg, et al.
Cancer Treatment Reviews|March 20, 2016
New perspectives on complement mediated immunotherapyGrzegorz Stasiłojć, Anders Österborg, Anna M Blom, et al.
Cancers|July 3, 2019
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical ApplicationTom A Mulder, Björn E Wahlin, Anders Österborg, et al.
Molecular Immunology|March 22, 2015
Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activationAnna M Blom, Anders Österborg, Tom E Mollnes, et al.
British Journal of Haematology|July 6, 2017
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I studyMaria Winqvist, Marzia Palma, Kia Heimersson, et al.
Experimental Hematology|September 2, 2015
Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative studySandra Eketorp Sylvan, Henriette Skribek, Stefan Norin, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 10, 2018
CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production ProfileIsabelle Magalhaes, Ingrid Kalland, James N Kochenderfer, et al.
Pageof 10